Claims for Patent: 11,857,547

Summary for Patent: 11,857,547

Title:	Compositions and methods for opioid antagonist delivery
Abstract:	Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof.
Inventor(s):	Haiyong Hugh Huang, Manjunath S. Shet
Assignee:	Purdue Pharma LP
Application Number:	US18/195,142
Patent Claims:	1. A parenteral formulation comprising an aqueous solution comprising about 1.5 mg of nalmefene free base or an equivalent amount of a pharmaceutically acceptable salt thereof and about 0.5% to about 1.0% (w/v) of a parenterally acceptable adjuvant, wherein the formulation provides a mean time to maximum plasma concentration of nalmefene (Tmax) shorter than the mean time to maximum plasma concentration of nalmefene of a comparative formulation without the said adjuvant, post intramuscular or subcutaneous injection to a population of subjects, wherein the adjuvant is magnesium chloride. 2. The parenteral formulation of claim 1, wherein the mean Tmax of the formulation is about 1.1 times shorter, about 1.2 times shorter, or about 1.3 times shorter than that of the comparative formulation without the adjuvant. 3. The parenteral formulation of claim 1, wherein the formulation comprises about 0.9% (w/v) of magnesium chloride. 4. The parenteral formulation of claim 1, comprising nalmefene hydrochloride in an amount equivalent to 1.5 mg nalmefene free base. 5. The parenteral formulation of claim 1, wherein the formulation provides a mean time to maximum plasma concentration of nalmefene (Tmax) shorter than the mean time to maximum plasma concentration of nalmefene of a comparative formulation without the said adjuvant, post intramuscular injection to a population of subjects. 6. The parenteral formulation of claim 1, wherein the formulation provides a mean time to maximum plasma concentration of nalmefene (Tmax) shorter than the mean time to maximum plasma concentration of nalmefene of a comparative formulation without the said adjuvant, post subcutaneous injection to a population of subjects. 7. A parenteral formulation comprising an aqueous solution comprising about 1.5 mg of nalmefene hydrochloride in an amount equivalent to 1.5 mg nalmefene free base and about 0.9% (w/v) of a parenterally acceptable adjuvant, wherein the formulation provides a mean time to maximum plasma concentration of nalmefene (Tmax) shorter than the mean time to maximum plasma concentration of nalmefene of a comparative formulation without the said adjuvant, post intramuscular injection to a population of subjects, wherein the adjuvant is magnesium chloride.